73 related articles for article (PubMed ID: 18624259)
1. Cascade screening in BRCA1/2 mutation carriers.
Cody N; Green A; McDevitt T; Lynch SA
Ir Med J; 2008 May; 101(5):140-2. PubMed ID: 18624259
[TBL] [Abstract][Full Text] [Related]
2. The phases of disclosing BRCA1/2 genetic information to offspring.
Clarke S; Butler K; Esplen MJ
Psychooncology; 2008 Aug; 17(8):797-803. PubMed ID: 18646247
[TBL] [Abstract][Full Text] [Related]
3. Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing.
Smith KR; West JA; Croyle RT; Botkin JR
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 2):385-92. PubMed ID: 10207644
[TBL] [Abstract][Full Text] [Related]
4. Uptake of testing for BRCA1/2 mutations in South East Scotland.
Holloway SM; Bernhard B; Campbell H; Lam WW
Eur J Hum Genet; 2008 Aug; 16(8):906-12. PubMed ID: 18285832
[TBL] [Abstract][Full Text] [Related]
5. Disparities in BRCA testing: when insurance coverage is not a barrier.
Olaya W; Esquivel P; Wong JH; Morgan JW; Freeberg A; Roy-Chowdhury S; Lum SS
Am J Surg; 2009 Oct; 198(4):562-5. PubMed ID: 19800469
[TBL] [Abstract][Full Text] [Related]
6. Can genetic testing guide treatment in breast cancer?
Tutt A; Ashworth A
Eur J Cancer; 2008 Dec; 44(18):2774-80. PubMed ID: 19027287
[TBL] [Abstract][Full Text] [Related]
7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
8. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
9. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort.
Fortuny D; Balmaña J; Graña B; Torres A; Ramón y Cajal T; Darder E; Gadea N; Velasco A; López C; Sanz J; Alonso C; Brunet J
Hum Reprod; 2009 Apr; 24(4):1000-6. PubMed ID: 19112076
[TBL] [Abstract][Full Text] [Related]
10. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring.
Bradbury AR; Patrick-Miller L; Pawlowski K; Ibe CN; Cummings SA; Olopade OI; Daugherty CK
Am J Med Genet C Semin Med Genet; 2008 Feb; 148C(1):70-7. PubMed ID: 18200524
[TBL] [Abstract][Full Text] [Related]
11. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
12. Penetrance of BRCA1/BRCA2 specific gene mutations in Iranian women with breast cancer.
Hashemian AH; Hajizadeh E; Kazemnejad A; Atri M; Mehdipour P
Saudi Med J; 2009 Jan; 30(1):41-4. PubMed ID: 19139771
[TBL] [Abstract][Full Text] [Related]
13. Familial effects of BRCA1 genetic mutation testing: changes in perceived family functioning.
Stroup AM; Smith KR
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):135-41. PubMed ID: 17220342
[TBL] [Abstract][Full Text] [Related]
14. [Information spreading about hereditary carriage of a BRCA1/2 mutation and ovarian cancer and rate of consultation of the concerned relatives].
Christophe V; Leroy T; Adenis C; Reich M; Vennin P
Bull Cancer; 2008 Apr; 95(4):395-402. PubMed ID: 18495568
[TBL] [Abstract][Full Text] [Related]
15. Transmission of mutant alleles to female offspring of BRCA1 carriers in Poland.
Gronwald J; Byrski T; Huzarski T; Narod SA; Lubinski J
J Med Genet; 2005 Jul; 42(7):e40. PubMed ID: 15994865
[No Abstract] [Full Text] [Related]
16. Intention to communicate BRCA1/BRCA2 genetic test results to the family.
Barsevick AM; Montgomery SV; Ruth K; Ross EA; Egleston BL; Bingler R; Malick J; Miller SM; Cescon TP; Daly MB
J Fam Psychol; 2008 Apr; 22(2):303-12. PubMed ID: 18410217
[TBL] [Abstract][Full Text] [Related]
17. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
18. Risk reducing mastectomy: outcomes in 10 European centres.
Evans DG; Baildam AD; Anderson E; Brain A; Shenton A; Vasen HF; Eccles D; Lucassen A; Pichert G; Hamed H; Moller P; Maehle L; Morrison PJ; Stoppat-Lyonnet D; Gregory H; Smyth E; Niederacher D; Nestle-Krämling C; Campbell J; Hopwood P; Lalloo F; Howell A
J Med Genet; 2009 Apr; 46(4):254-8. PubMed ID: 18996907
[TBL] [Abstract][Full Text] [Related]
19. Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.
James PA; Harris M; Lindeman GJ; Mitchell G
J Med Genet; 2008 Nov; 45(11):765-6. PubMed ID: 18978334
[No Abstract] [Full Text] [Related]
20. Phenocopies in breast cancer 1 (BRCA1) families: implications for genetic counselling.
Gronwald J; Cybulski C; Lubinski J; Narod SA
J Med Genet; 2007 Apr; 44(4):e76. PubMed ID: 17400795
[No Abstract] [Full Text] [Related]
[Next] [New Search]
